Reminyl, Galantamine

Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 13 of 13 in Reminyl, Galantamine (generic)

  1. Upcoming Events: A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's DataRead the original story w/Photo

    15 hrs ago | Seeking Alpha

    Welcome to your weekly digest of approaching regulatory and clinical readouts. Data from BioMarin's Phase II trial of the achondroplasia project BMN 111, expected this month or next, will allow the company to decide whether to test a higher dose.


  2. Antidementia drug treatment in dementia networks in Germany: use...Read the original story

    Friday | BioMed Central

    German Center for Neurodegenerative Diseases , Research Group "Interventional Health Care Research", Site Rostock/ Greifswald, Ellernholzstr. 1-2, Greifswald D-17487, Germany Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, Ernst-Moritz-Arndt-University Greifswald, Ellernholzstrasse 1-2, Greifswald D-17487, Germany Background Dementia networks in Germany constitute a specialised setting for integrated dementia care and have shown benefits on relevant outcomes, including those of drug treatment.


  3. The influence of cholinesterase inhibitor therapy for dementia on...Read the original story

    Monday Apr 27 | BioMed Central

    Division of Geriatric Medicine, Department of Medicine, University of Ottawa, The Ottawa Hospital, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Department of Epidemiology & Community Medicine, University of Ottawa; Ottawa Hospital Research Institute; ICES uOttawa, The Ottawa Hospital, ASB1-003, 1053 Carling Avenue, Ottawa K1Y 4E9, Ontario, Canada Background Cholinesterase inhibitors are used to treat the symptoms of dementia and can theoretically cause bradycardia. Previous studies suggest that patients taking these medications have an increased risk of undergoing pacemaker insertion.


  4. Effective Drug Therapy for Alzheimer's Disease Remains ElusiveRead the original story

    Mar 13, 2015 | ASHP

    In the two years since the United States set a national goal of effectively preventing or treating Alzheimer's disease by 2025, no new therapies have been approved, and recent clinical trials of investigational drugs have proved disappointing. According to the Pharmaceutical Research and Manufacturers of America, about 83% of drugs that are tested in clinical trials never earn FDA approval.


  5. memantine, Namenda, Namenda XRRead the original story w/Photo

    Feb 24, 2015 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.


  6. AB Science : Successful Completion Of Futility Test For Masitinib In Alzheimer's DiseaseRead the original story

    Feb 9, 2015 | BioSpace

    AB Science SA , a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors , today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease. Based on these results, the Independent Data Safety Monitoring Committee has recommended the continuation of the study.


  7. Holy moly? Snowdrops, like these at Colesbourne Park, may be the medicinal herb cited by HomerRead the original story w/Photo

    Feb 5, 2015 | Oxford Times

    They may only be a few inches high, with tiny white flowers, but snowdrops cause great excitement in February. They welcome in spring, albeit early spring, and we can't wait to get among them in February.


  8. Pharmacological treatments for frontotemporal dementias: a systematic ...Read the original story

    Dec 29, 2014 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The objective of this review is to summarize the current data on the pharmacological treatments for frontotemporal dementias from randomized controlled trials.


  9. ENTREVESTOR: P.E.I. firm gains traction with drugRead the original story w/Photo

    Dec 18, 2014 | The Chronicle Herald

    Denis Kay has been a scientist for a long time, but he's most thrilled by his current role working on a promising drug for Alzheimer's disease. Alzheimer's is an escalating problem in aging societies.


  10. Cholinergic Stimulation Enhances Bayesian Belief Updating in the Deployment of Spatial AttentionRead the original story

    Nov 23, 2014 | CiteULike

    The Journal of Neuroscience , Vol. 34, No. 47. , pp. 15735-15742, doi:10.1523/jneurosci.0091-14.2014 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.


  11. Thousands 'too ashamed' to tell family or doctors they have...Read the original story w/Photo

    Oct 26, 2014 | Daily Mail

    Thousands 'too ashamed' to tell family or doctors they have dementia: Report compares stigma to that of HIV in the 1980s It compares the stigma to that of HIV and Aids in the 1980s and says as many as a quarter of those suffering are refusing to speak out. Doctors say patients tell them how their friends 'disappeared' after they were diagnosed and in some cases how their own children have stopped visiting.


  12. Hyderabad scientist elected as fellow of Indian National Science AcademyRead the original story w/Photo

    Oct 24, 2014 | DNA India

    The Indian National Science Academy , apex body of Indian scientists, has elected Chief Scientist of CSIR-IICT, Srivari Chandrasekhar, as a fellow from the year 2015. The recognition has been accorded for his contribution in the area of organic chemistry for the last two decades, according to a statement from CSIR-IICT .


  13. Neurotrope Tackles Alzheimer's Disease With Novel MechanismRead the original story w/Photo

    Oct 20, 2014 | Seeking Alpha

    Bryostatin-1 activates protein kinase C and represents a novel treatment option for AD that is supported by extensive preclinical data. Neurotrope has a basic market capitalization of only $14 million, with $10+ million in cash in the bank and data from a Phase 2a study coming in early 2015.